KSRT1: Regulation of Translation Initiation in Eukaryotic Cells
KSRT1: Regulation of Translation Initiation in Eukaryotic Cells
Eukaryotic Translation Initiation Factor 2-alpha Kinase (nonspecified subtype) (Eukaryotic Translation Initiation Factor 2-alpha Kinase), also known as KSRT1, is a protein that plays a crucial role in the process of translation initiation in eukaryotic cells. It is a key regulator of the 40S ribosome complex, which is responsible for translating mRNAs into functional proteins. KSRT1 functions as a negative regulator of the initiation complex, preventing the access of tRNA and mRNA to the A-site on the ribosome.
KSRT1 was first identified in 1997 and has since been widely studied to understand its role in translation initiation. It is a 21-kDa protein that contains a nucleotide-binding oligomerization domain (NBO), a catalytic domain, and a C-terminal TIR domain. The NBO is responsible for binding to the A-site on the ribosome, while the TIR domain is involved in the regulation of protein-protein interactions.
KSRT1 functions as a negative regulator of the initiation complex by preventing the access of tRNA and mRNA to the A-site on the ribosome. It does this by forming a covalent complex with the alpha-2 component of the initiation complex, which is responsible for recognizing the A-site on the ribosome. The NBO of KSRT1 binds to the A-site with high affinity, while the TIR domain interacts with the alpha-2 component to prevent the binding of tRNA and mRNA.
KSRT1 has been shown to play a role in various cellular processes, including cell growth, cell division, and neurodegeneration. It has been shown to regulate the number of ribosomes present in the cell, as well as the translation rate. It has also been shown to interact with various protein partners, including the transcription factor, p53.
KSRT1 has also been identified as a potential drug target and may be a biomarker for various diseases. For example, KSRT1 has been shown to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. This suggests that targeting KSRT1 may be a promising strategy for the development of new cancer therapies.
In addition to its potential as a drug target, KSRT1 also has implications for the study of translation regulation more broadly. The regulation of translation initiation is a complex process that involves the interplay of numerous factors, including the ribosome, the DNA double helix, and various proteins. KSRT1's role in this process sheds light on the mechanisms underlying translation regulation and may have implications for the development of new therapeutic strategies.
In conclusion, Eukaryotic Translation Initiation Factor 2-alpha Kinase (nonspecified subtype) (KSRT1) is a protein that plays a crucial role in the process of translation initiation in eukaryotic cells. It is a key regulator of the 40S ribosome complex and functions as a negative regulator of the initiation complex by preventing the access of tRNA and mRNA to the A-site on the ribosome. The regulation of translation initiation by KSRT1 has implications for the development of new therapeutic strategies and is an attractive target for further research.
Protein Name: Eukaryotic Translation Initiation Factor 2-alpha Kinase (nonspecified Subtype)
The "Eukaryotic translation initiation factor 2-alpha kinase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Eukaryotic translation initiation factor 2-alpha kinase comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
Eukaryotic translation initiation factor 2B | Eukaryotic translation initiation factor 3 (eIF-3) complex | Eukaryotic Translation Initiation Factor 4A (eIF-4A) | Eukaryotic Translation Initiation Factor 4E Binding Protein | EVA1A | EVA1A-AS | EVA1B | EVA1C | EVC | EVC2 | EVI2A | EVI2B | EVI5 | EVI5L | EVL | EVPL | EVPLL | EVX1 | EVX1-AS | EVX2 | EWSAT1 | EWSR1 | EXD1 | EXD2 | EXD3 | EXO1 | EXO5 | EXOC1 | EXOC1L | EXOC2 | EXOC3 | EXOC3-AS1 | EXOC3L1 | EXOC3L2 | EXOC3L4 | EXOC4 | EXOC5 | EXOC5P1 | EXOC6 | EXOC6B | EXOC7 | EXOC8 | Exocyst complex | EXOG | EXOGP1 | Exon junction complex | EXOSC1 | EXOSC10 | EXOSC10-AS1 | EXOSC2 | EXOSC3 | EXOSC4 | EXOSC5 | EXOSC6 | EXOSC7 | EXOSC8 | EXOSC9 | Exosome Complex | EXPH5 | EXT1 | EXT2 | EXTL1 | EXTL2 | EXTL2P1 | EXTL3 | EXTL3-AS1 | EYA1 | EYA2 | EYA3 | EYA4 | EYS | EZH1 | EZH2 | EZHIP | EZR | F10 | F11 | F11-AS1 | F11R | F12 | F13A1 | F13B | F2 | F2R | F2RL1 | F2RL2 | F2RL3 | F3 | F5 | F7 | F8 | F8A1 | F8A2 | F8A3 | F9 | FA2H | FAAH | FAAH2 | FAAHP1 | FAAP100
